Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes (Q38241171)

31 August 2017

title

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes (English)

1 reference

31 August 2017

0 references

Jennifer M Trujillo

1

1 reference

31 August 2017

Wesley Nuffer

series ordinal

2

1 reference

31 August 2017

language of work or name

English

0 references

publication date

18 August 2014

1 reference

Annals of Pharmacotherapy

31 August 2017

published in

1 reference

31 August 2017

volume

48

1 reference

31 August 2017

issue

11

1 reference

31 August 2017

page(s)

1494-1501

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545807

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545807

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545807

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545807

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545807

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545807

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545807

HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545807

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545807

Syntaxin-3 regulates newcomer insulin granule exocytosis and compound fusion in pancreatic beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545807

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545807

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545807

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545807

A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014545807

21 January 2018

Identifiers

DOI

10.1177/1060028014545807

1 reference

31 August 2017

1 reference